NeuroRx, Inc.

69 articles with NeuroRx, Inc.

• 

  Biopharma Update on the Novel Coronavirus: June 24

  6/24/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

• Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital

  6/11/2020

  RELIEF THERAPEUTICS Holding AG “Relief” and its U.S. partner, NeuroRx, Inc. announced that Houston Methodist Hospital is participating in their Phase 2 clinical trial evaluating RLF-100 as a research intervention for critically ill patients with COVID-19 and respiratory failure.

• Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

  6/8/2020

  RELIEF THERAPEUTICS Holding AG “Relief” and its U.S. partner, NeuroRx, Inc. announced that the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with respiratory failure has been expanded to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators.

• Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

  6/1/2020

  First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100

• 

  Clinical Catch-Up: May 11-15

  5/18/2020

  Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

• Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

  5/14/2020

  Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilation

• Relief Therapeutics Announces Filing of IND for Phase 2/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury

  5/11/2020

  Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU care

• NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference

  2/10/2020

  NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am .  The company's CEO, Dr. Jonathan Javitt will be presenting an overview of recent results obtained with NRX-101, the only clinical stage drug in current development for suicidal bipolar depression.  NRX-101 has been granted B

• NeuroRx Drug for Suicidal Bipolar Depression Receives Notification of Patent Allowance

  1/8/2020

   NeuroRx, Inc announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need that results in the death of more than 25,000 Americans each year.

• NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101

  10/23/2019

  NeuroRx, Inc announced that it has signed an agreement with GEM Global Yield LLC SCS, the New York based private alternative investment group to provide the NeuroRx with up to HK$ 750 million over a 30 month term following a public listing of NeuroRx's common stock.

• NeuroRX to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

  9/9/2019

  In addition to the presentation by Dr. Jonathan C. Javitt, the Company's CEO, the Company will be available for 1x1 meetings.

• NeuroRx Initiates Pivotal Study for NRX-101, a Breakthrough Designation Therapy Targeting Suicidal Bipolar Depression

  7/9/2019

   NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it has initiated a pivotal Phase 2b/3 study for NRX-101 for the treatment of patients with Severe Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB)

• NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention

  6/3/2019

  First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation

• 

  Clinical Catch-up from Last Week: May 28-31

  6/3/2019

  Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.

• NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

  5/30/2019

   NeuroRx, a clinical stage biopharma company focused on development of drugs to target suicidal depression and PTSD, announced statistically significant final results from its Phase 2 STABIL-B study of NRX-101 versus lurasidone in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior (ASIB).

• NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

  12/13/2018

  Findings suggest potential for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine

• NeuroRx Receives FDA Breakthrough Therapy Designation for NRX-101, First Oral Drug Targeting Suicidal Bipolar Depression

  11/13/2018

  NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for development of NRX-101

• NeuroRx, Inc. Completes Phase 2b/3 Feasibility Enrollment for First Glx-Targeted Oral Drug Targeting Suicidal Bipolar Depression

  6/11/2018

  NRX-101 was awarded FAST TRACK designation by the FDA in August 2017 as an experimental agent for the treatment of Severed Bipolar Depression with Acute Suicidal Ideation or Behavior.

• NeuroRx Retains J.P. Morgan as Financial Advisor

  1/3/2018

  NeuroRx is developing a sequential treatment regimen of NRX-100 and NRX-101, and will begin enrolling patients shortly in a Phase 2b/3 pivotal study targeting severe bipolar depression in patients with ASIB.